Drug profile

The FDA adverse-event record for Fluralaner/Moxidectin Spot-On

3,391 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Fluralaner/Moxidectin Spot-On. See the species affected, top reactions, and outcomes below.

3,391
adverse-event reports
3.2%
death-coded share
Cat
most-reported species
603
Application site hair loss - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
3,391
Total Reports
107
Deaths Reported
3.2%
Death Rate

Active Ingredients

Fluralaner/Moxidectin Spot-On

Administration Routes

TopicalUnknownOralSubcutaneousOtherRespiratory (Inhalation)IntraocularImmersionRectalOphthalmic

Species Affected

Cat 2,799
Unknown 407
Human 179
Dog 5
Gerbil 1

Most Affected Breeds

Domestic Shorthair 1,812
Unknown 596
Domestic Longhair 230
Cat (unknown) 224
Domestic Mediumhair 194
Crossbred Feline/cat 48
Maine Coon 48
Siamese 45
Cat (other) 22
Ragdoll 21

Most Reported Reactions

Application site hair loss 603
Lack of efficacy (ectoparasite) - flea 525
Lethargy (see also Central nervous system depression in 'Neurological') 231
Emesis (multiple) 186
Underfilling, Container 162
Foaming at the mouth 158
Behavioural disorder NOS 134
Containers, Leaking 134
Application site stickiness 133
Application site alopecia 121
Vomiting 116
Hypersalivation 114

Outcome Breakdown

Ongoing
2,076 (69.6%)
Recovered/Normal
622 (20.8%)
Outcome Unknown
162 (5.4%)
Died
67 (2.2%)
Euthanized
40 (1.3%)
Recovered with Sequela
17 (0.6%)

Fluralaner/Moxidectin Spot-On Adverse Event Insights

3,391 reports name Fluralaner/Moxidectin Spot-On; 107 recorded a death outcome (3.2% of reported events, not a population-level mortality rate). Active ingredient: Fluralaner/Moxidectin Spot-On. Administration routes: Topical, Unknown, Oral, Subcutaneous.

By species: Cat (2,799 reports), Unknown (407 reports), Human (179 reports). By breed: Domestic Shorthair (1,812), Unknown (596), Domestic Longhair (230).

Leading clinical signs: Application site hair loss (603), Lack of efficacy (ectoparasite) - flea (525), Lethargy (see also Central nervous system depression in 'Neurological') (231), Emesis (multiple) (186). Outcome, 2,984 coded reports: Ongoing leads at 69.6%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.